REVANESSE referencias disponibles en ALLPARA para uso profesional, de origen directo y certificadas en cada envío.
Revanesse Lips™+
Revanesse Lips+ is a biocompatible, biodegradable, non-pyrogenic, sterile, injectable viscoelastic hydrogel, clear and colourless, from Prollenium Medical Technologies in Aurora, Canada, developed for lip augmentation. It is indicated for submucosal implantation in patients 22 years of age or older and is FDA approved under PMA P160042/S010. The gel carries 25 mg/mL of bioresorbable, BDDE cross-linked hyaluronic acid, produced by the Streptococcus species of bacteria, with 0.3% lidocaine and is intended for professional use. A box holds two 1.2 mL glass syringes and two 0.5 inch 30-gauge sterile needles.
*Note: This product is FDA-approved in the United States. Regulatory status and availability may vary by country. Please contact ALLPARA to confirm availability for your market.
Principales ventajas de Revanesse Lips™+
- BDDE cross-linked hyaluronic acid 25 mg/mL with 0.3% lidocaine
- Indicated specifically for lip augmentation by submucosal implantation
- FDA approved under PMA P160042/S010
- Supplied with two 0.5 inch 30-gauge sterile needles
- Supplied as two 1.2 mL glass syringes per box
- Hyaluronic acid produced by the Streptococcus species of bacteria
- Removable label portion for the patient record
Indicaciones y uso profesional
Indicaciones principales
- Lip augmentation by submucosal implantation
Uso profesional
For professional use. Revanesse Lips+ is administered by qualified physicians trained in the proper injection technique, and is not for retail sale or self-administration. It is placed by submucosal implantation in the lip using the 0.5 inch 30-gauge needles supplied. Its approval was supported by two clinical studies: a multicentre, double-blind, randomised, controlled treatment study enrolling 158 subjects over 10 months, and a multicentre, open-label retreatment study of 84 of those subjects over a further 8 months, with lip fullness assessed on the 5-point Lip Fullness Grading Scale.
Zonas de tratamiento
- Lips
Perfil del paciente
Indicated for patients 22 years of age or older seeking lip augmentation. It must not be used in patients who develop hypertrophic scarring or keloid formation, in patients with evidence of scars at the intended treatment sites, in patients with acne or other inflammatory skin disease, in patients with multiple severe allergies or a history of allergy, or in patients with unattainable expectations. It must never be used in conjunction with laser, intense pulsed light, chemical peeling or dermabrasion treatments, or with over-the-counter or prescription wrinkle treatments within 4 weeks of treatment.
Cómo funciona Revanesse Lips™+
Lips+ is placed submucosally in the lip, where the cross-linked hyaluronic acid hydrogel adds volume directly. It is the only reference in the Revanesse range with an indication written specifically and solely for lip augmentation, which is reflected in its delivery: a fine 0.5 inch 30-gauge needle rather than the 27G used by the deeper-placed grades. The 0.3% lidocaine is present for injection comfort. Each syringe carries a removable portion of its label that can be affixed to the patient record for traceability.
Por qué comprar en Allpara
Allpara ofrece productos REVANESSE originales y verificados de proveedores seleccionados, con trazabilidad completa de lotes y asesoramiento experto. Atendemos a clínicas y profesionales de la estética con productos con certificado CE, entrega rápida en toda la UE desde nuestro almacén en la UE y precios profesionales competitivos. Nuestra prioridad es la seguridad, la satisfacción y los resultados de sus pacientes, con un servicio posventa dedicado para su tranquilidad.
Preguntas frecuentes
How does Lips+ differ from the other Revanesse references?
Its indication is written solely for lip augmentation, by submucosal implantation, in patients 22 years of age or older. It shares the 25 mg/mL BDDE cross-linked hyaluronic acid and 0.3% lidocaine of Contour+ and Sculpt+, but is supplied with finer 0.5 inch 30-gauge needles rather than 27G.
What clinical evidence supports Revanesse Lips+?
Two studies formed the basis of the PMA approval decision: a multicentre, double-blind, randomised, controlled treatment study of 158 subjects lasting 10 months, and a multicentre, open-label retreatment study of 84 of those subjects lasting a further 8 months. Effectiveness was measured as change in overall Lip Fullness Grading Scale score for both lips together.
Más productos de Prollenium Medical Technologies
Alternativas para la clínica
Retome donde lo dejó
Revanesse Lips™+
Revanesse Lips+ is a biocompatible, biodegradable, non-pyrogenic, sterile, injectable viscoelastic hydrogel, clear and colourless, from Prollenium Medical Technologies in Aurora, Canada, developed for lip augmentation. It is indicated for submucosal implantation in patients 22 years of age or older and is FDA approved under PMA P160042/S010. The gel carries 25 mg/mL of bioresorbable, BDDE cross-linked hyaluronic acid, produced by the Streptococcus species of bacteria, with 0.3% lidocaine and is intended for professional use. A box holds two 1.2 mL glass syringes and two 0.5 inch 30-gauge sterile needles.
*Note: This product is FDA-approved in the United States. Regulatory status and availability may vary by country. Please contact ALLPARA to confirm availability for your market.
Principales ventajas de Revanesse Lips™+
- BDDE cross-linked hyaluronic acid 25 mg/mL with 0.3% lidocaine
- Indicated specifically for lip augmentation by submucosal implantation
- FDA approved under PMA P160042/S010
- Supplied with two 0.5 inch 30-gauge sterile needles
- Supplied as two 1.2 mL glass syringes per box
- Hyaluronic acid produced by the Streptococcus species of bacteria
- Removable label portion for the patient record
Indicaciones y uso profesional
Indicaciones principales
- Lip augmentation by submucosal implantation
Uso profesional
For professional use. Revanesse Lips+ is administered by qualified physicians trained in the proper injection technique, and is not for retail sale or self-administration. It is placed by submucosal implantation in the lip using the 0.5 inch 30-gauge needles supplied. Its approval was supported by two clinical studies: a multicentre, double-blind, randomised, controlled treatment study enrolling 158 subjects over 10 months, and a multicentre, open-label retreatment study of 84 of those subjects over a further 8 months, with lip fullness assessed on the 5-point Lip Fullness Grading Scale.
Zonas de tratamiento
- Lips
Perfil del paciente
Indicated for patients 22 years of age or older seeking lip augmentation. It must not be used in patients who develop hypertrophic scarring or keloid formation, in patients with evidence of scars at the intended treatment sites, in patients with acne or other inflammatory skin disease, in patients with multiple severe allergies or a history of allergy, or in patients with unattainable expectations. It must never be used in conjunction with laser, intense pulsed light, chemical peeling or dermabrasion treatments, or with over-the-counter or prescription wrinkle treatments within 4 weeks of treatment.
Cómo funciona Revanesse Lips™+
Lips+ is placed submucosally in the lip, where the cross-linked hyaluronic acid hydrogel adds volume directly. It is the only reference in the Revanesse range with an indication written specifically and solely for lip augmentation, which is reflected in its delivery: a fine 0.5 inch 30-gauge needle rather than the 27G used by the deeper-placed grades. The 0.3% lidocaine is present for injection comfort. Each syringe carries a removable portion of its label that can be affixed to the patient record for traceability.
Por qué comprar en Allpara
Allpara ofrece productos REVANESSE originales y verificados, con trazabilidad completa de lotes, stock con certificado CE, entrega rápida en toda la UE y servicio posventa experto.
Preguntas frecuentes
How does Lips+ differ from the other Revanesse references?
Its indication is written solely for lip augmentation, by submucosal implantation, in patients 22 years of age or older. It shares the 25 mg/mL BDDE cross-linked hyaluronic acid and 0.3% lidocaine of Contour+ and Sculpt+, but is supplied with finer 0.5 inch 30-gauge needles rather than 27G.
What clinical evidence supports Revanesse Lips+?
Two studies formed the basis of the PMA approval decision: a multicentre, double-blind, randomised, controlled treatment study of 158 subjects lasting 10 months, and a multicentre, open-label retreatment study of 84 of those subjects lasting a further 8 months. Effectiveness was measured as change in overall Lip Fullness Grading Scale score for both lips together.